PTS-ID™
Post-Traumatic Stress Disorder (PTSD) Screening & Triage
Key Facts
About Polaris Genomics
Polaris Genomics is a privately held, veteran-founded diagnostics company established in 2015, headquartered in Rockville, Maryland. The company's core offering is the ADAPT Neuropsychiatric Biomarker Discovery Platform™, a research tool that analyzes genetic and transcriptomic data to identify RNA expression profiles correlated with conditions like PTSD, depression, and anxiety. Polaris is translating this platform into clinical diagnostics, beginning with PTS-ID™, a first-of-its-kind blood test for PTSD screening and triage. The company targets partnerships with pharmaceutical, academic, and clinical research organizations to advance biomarker-driven drug development and clinical tools.
View full company profile